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Objective: Congenital heart defects with major aortopulmonary collateral
arteries show marked variability in the size and distribution of native
pulmonary arteries. We sought to classify the size and distribution of
native pulmonary arteries and to determine their influence on surgical
outcome.
Methods: Between 1989 and 2002, 164 patients underwent surgical
intervention for congenital heart defects with major aortopulmonary
collateral arteries (median age, 10 months). Three patterns of native
pulmonary arteries were identified: intrapericardial native pulmonary
arteries present (group I); confluent intrapulmonary native pulmonary
arteries without intrapericardial native pulmonary arteries (group II); and
nonconfluent intrapulmonary native pulmonary arteries (group III). Thir-
ty-seven (23%) patients had single-stage and 76 (47%) patients had
multistage complete repair. Thirty (18%) patients await septation, and 8
(5.0%) patients are not septatable. Follow-up is 98% complete (median follow-up,
5.8 years).
Results: In the 164 patients there were 15 (9.1%) early and 12 (7.3%) late deaths.
Early mortality after complete repair was 4.4% (n 5). Actuarial survival was 90%
 3% and 85%  4% at 1 and 10 years, respectively. Actuarial freedom from
surgical or catheter reintervention in septated patients was 77%  4% and 45% 
8% at 1 and 10 years, respectively. On multivariate analysis, the morphology of
the native pulmonary arteries was the only factor that influenced actuarial survival
after complete repair (P  .04). Group III had the highest risk of death after
septation (P  .008). Group II fared better than group III after the initial operation
(P  .05).
Conclusions: Current classifications of congenital heart defects with major aorto-
pulmonary collateral arteries are based on the presence or absence of intrapericardial
pulmonary arteries. We have identified a subgroup without intrapericardial native
pulmonary arteries but with confluent intrapulmonary native pulmonary arteries.
This group has a better outcome than those with nonconfluent intrapulmonary native
pulmonary arteries.
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Congenital heart defects (CHDs) with majoraortopulmonary collateral arteries (MAP-CAs) are characterized by marked morpho-logic variability in the source and arboriza-tion pattern of the pulmonary bloodsupply.1-3 Treatment has evolved from pal-
liative shunting or interruption of collateral arteries in the
1970s to reconstruction of the pulmonary arteries with uni-
focalization to the right ventricle with or without ventricular
septal defect (VSD) closure.4-10 This progress has been
related to the better characterization of the MAPCAs and
native pulmonary arteries (NPAs) together with improve-
ments in the surgical care of small infants. Classification of
the pulmonary blood supply in patients with CHDs and
MAPCAs is necessary to plan appropriate surgical manage-
ment. However, the classification of pulmonary blood sup-
ply is difficult because of the complex variability in the
morphology of the NPAs and MAPCAs. The aim of this
study was to determine the influence of anatomic variables
that characterize the pulmonary blood supply on outcome in
patients who underwent surgical intervention for CHDs and
MAPCAs at our institution.
Patients and Methods
Between January 1989 and December 2002, 167 patients with
CHDs and MAPCAs were referred for treatment to the Diana
Princess of Wales Children’s Hospital, Birmingham, United King-
dom. Three (1.8%) patients with univentricular connections de-
clined operations and were not included in this study. All other
patients referred were entered into the surgical program.
This study involved the retrospective review of hospital records
and echocardiographic and cardiac catheterization data, as well as
assessment of the current clinical status. For the purposes of
analysis, the 30-day mortality and actuarial survival after the first
operation and complete repair with VSD closure, as well as the
actuarial freedom from surgical and cardiac catheter reinterven-
tion, were used as outcome measures. These were evaluated with
regard to a series of morphologic variables that defined pulmonary
blood supply.
All patients have been followed up either by a pediatric cardi-
ologist in our own unit or in the patients’ referring hospital.
Clinical status was graded by using the New York Heart Associ-
ation functional classification. Follow-up was complete, with a
median interval of 5.8 years after the first operation (range, 1
day-23.4 years) and 3.9 years after complete repair (range, 1
day-12.9 years).
Of the 164 patients who underwent surgical intervention for
CHDs with MAPCAs, 76 (47%) were male. The median age at the
time of the first operation was 10 months (range, 1 day-47 years),
and 87 (53%) were less than 1 year of age at the time of the first
operation. The most common cardiac malformation was pulmo-
nary atresia and VSD (n  153 [93.3%]). The remaining 11
patients had a variety of other diagnoses (Table 1). Four patients
with pulmonary atresia and VSDs had additional cardiac anoma-
lies, 3 with an anomalous left anterior descending coronary artery
arising from the right coronary artery and 1 with partial anomalous
pulmonary venous return to the superior vena cava. Thirty (18%)
patients had associated noncardiac anomalies. Of these, 22 (73%)
patients had the Di George syndrome with chromosome 22q11
microdeletion, although fluorescent in situ hybridization (FISH)
was not routinely performed at our institution until 1995.
Each patient had a median number of 4 MAPCAs (range, 1-7).
In the majority of patients (n  161 [98.2%]), these originated
from the descending thoracic aorta or the aortic arch. In 3 (1.8%)
patients the MAPCAs also arose from the right coronary artery.
Twenty-five patients were initially treated at other centers. Eight
patients had iatrogenic complications after these initial surgical
procedures, which significantly altered our surgical strategy. The
majority of patients (n  138 [84%]) presented with varying
degrees of cyanosis, whereas 26 (16%) patients presented with
congestive cardiac failure.
Assessment and Classification of the Pulmonary Blood
Supply
Cardiac catheterization studies were analyzed to delineate the
pulmonary blood supply and the intracardiac morphology and to
collect haemodynamic data. NPAs were outlined by means of
direct injection of MAPCAs through shunts or from retrograde
pulmonary venous wedge studies. The vascular morphology was
classified to allow for detailed analysis to relate these anatomic
variables of the pulmonary blood supply to surgical outcomes.
First, 3 groups of NPA morphology were identified. In group I
(n  111) native intrapericardial pulmonary arteries were present.
In group II (n  30) intrapericardial NPAs were absent, but there
were confluent intrapulmonary pulmonary arteries in one or both
lungs. In group III (n  23) both the intrapericardial pulmonary
arteries and the confluent intrapulmonary pulmonary arteries were
absent.
Second, central and distal pulmonary artery size was classified
as adequate if greater than 75% of predicted size, hypoplastic
between 50% and 75%, and very hypoplastic if smaller than 50%
of expected size.11
Third, MAPCAs were classified as large if in excess of 2 mm
in diameter, medium if between 1 and 2 mm in diameter, and small
if less than 1 mm in diameter.11
Using these rules, we could estimate pulmonary blood supply
in patients in whom either the NPAs or MAPCAs constituted the
predominant pulmonary blood source. It was more difficult to
assess pulmonary blood supply when NPAs and MAPCAs com-
bined with a varying degree of dual blood supply. To allow for
TABLE 1. Primary cardiac anatomy among patients with
CHDs and MAPCAs
Pulmonary atresia and ventricular septal defect 153
Tetralogy of Fallot 5
Congenitally corrected transposition of the great
arteries
2
Simple transposition of the great arteries 1
Pulmonary atresia and intact ventricular septum 1
Truncus arteriosus 1
Left atrial isomerism, atrioventricular septal defect, and
total anomalous pulmonary venous drainage
1
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ease of statistical analysis among these patients, we made an
estimation of the overall caliber of distal pulmonary blood supply,
which encompassed the size of the NPAs and MAPCAs and the
presence and extent of dual blood supply. Pulmonary blood supply
was thus classified as adequate, medium, or small.
This classification system was, in part, subjective. Neverthe-
less, we believed that it provided the best approximation of the
pulmonary blood supply, which would allow more detailed statis-
tical analysis of outcome.
Surgical Intervention
The technical aspects of surgical intervention have evolved over
the period of review. Many aspects are similar to those described
in other centers.12-23 Our first single-stage repair with VSD closure
was performed in 1991, and when possible, this is our procedure of
choice. Primary focalization of the reconstructed pulmonary arter-
ies and MAPCAs to the right ventricle with a valved conduit is our
favored method of restoring pulmonary artery continuity, even
when the VSD cannot be closed at the initial procedure. A restric-
tive conduit from the right ventricle to the pulmonary artery is used
in patients in whom the VSD cannot be closed (ie, similar to the
VSD pulmonary stenosis situation, such that the distal pulmonary
arteries are not subjected to high pressure or excessive blood flow).
In addition, this technique facilitates subsequent catheterization
and surgical intervention to enlarge the distal pulmonary arteries.
Palliative unifocalization with a systemic shunt is still occasionally
used, but this is now unusual in our practice.
Mobilization and delineation of the MAPCAs and often the
proximal NPAs is usually achieved through a short thoracotomy
on the side of the descending thoracic aorta. This approach pro-
vides good surgical exposure of the mediastinal structures and
clear delineation of the NPAs within the pulmonary fissures. There
is thus less risk of damage to the phrenic or vagus nerves or the
mediastinal vessels. This is then followed by a midline sternotomy
giving access for reconstruction of the vessels by using hypother-
mic cardiopulmonary bypass with periods of circulatory arrest if
required. The distal vessels are sometimes controlled with small
Yarsargil aneurysm clips (Aesculap AG & Co KG, Tuttlingen,
Germany) to restrict the periods of circulatory arrest. Anastomoses
between the pulmonary artery tissue and the collateral tissue are
preferred but not always possible. Patch enlargement of the vessels
is generally achieved by using pulmonary homograft patch mate-
rial, although polytetrafluroethylene* tube conduits and Medtronic
Contegra pulmonary valved conduits (Medtronic UK Ltd,
Watford, United Kingdom) are used when necessary.
The decision whether to close the VSD can be difficult. We
prefer to depend on the preoperative evaluation of the vessels
together with a subjective evaluation of the success of the anasta-
mosis and reconstruction at the time of the operation to determine
whether the VSD can be closed. Tetralogy of Fallot can be repaired
to a single lung circulation with a low postoperative right ventric-
ular/left ventricular (RV/LV) pressure ratio. In patients with CHDs
and MAPCAs, we consider 15 pulmonary segments (ie, equivalent
to 11⁄2 lungs) as safe for complete repair with VSD closure. If in
doubt, the VSD is not closed.
Aprotinin (Ferring Pharmaceuticals A/S, Copenhagen, Den-
mark) and tissue glues, such as Beriplast P (Aventis Behring
GmbH, Marburg, Germany), are used to help with hemostasis. In
addition, the native pericardial envelope is carefully preserved and
closed with a Supple Peri-Guard pericardial membrane (Biovas-
cular Inc, Saint Paul, Minn) to facilitate reoperative procedures.
We have a low threshold for leaving the sternum open, although
we try to close the skin in the immediate postoperative period.
Postoperatively, the majority of patients have a cardiac cathe-
terization study before discharge to evaluate the quality and com-
pleteness of MAPCA recruitment and to plan further surgical or
catheter intervention. Furthermore, all patients are readmitted
within 6 months after the operation for another cardiac catheter-
ization study, and any residual abnormalities are aggressively
treated at that time.
The surgical management of the 164 patients is summarized in
Figure 1. Essentially, 4 main management strategies have evolved:
single-stage repair with VSD closure, single-stage unifocalization
to the right ventricle, multistage focalization, and a palliative
operations without the prospect of VSD closure.
Statistical Analysis
Data have been examined by means of analysis of variance with a
commercial statistical software package (SPSS for Windows, ver-
sion 11; SPSS Inc, Chicago, Ill). Continuous variables are ex-
pressed as medians and ranges, and comparative univariate anal-
yses have been made with the Mann-Whitney U test or the
*Gore-Tex tube conduits, registered trademark of W. L. Gore & Associates,
Inc, Newark, Del.
Figure 1. Surgical algorithm for treatment of patients with CHDs and MAPCAs.
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Wilcoxon signed- rank test. Binomial or ordinal data are expressed
as percentages, and comparative univariate analyses have been
made with the 2 test, the 2-sided Fisher exact test, or binomial
logistic regression, as appropriate.
The effect of the morphologic variables on outcome was tested
by using univariate and multivariate analyses. Univariate analyses
of early outcome measures have been made with the 2 test, the
2-sided Fisher exact test, and binomial logistic regression. Vari-
ables with a P value of less than or equal to .1 were included in a
stepwise logistic regression model. Results of these multivariate
analyses have been expressed as odds ratios with 95% confidence
intervals (CIs) for variables with a P value of less than .05.
Actuarial survival, freedom from reoperation, and freedom from
reintervention were estimated by using the Kaplan-Meier product
limit method. These results have been expressed as a probability
estimate 1 SEM. Univariate analyses of actuarial outcome mea-
sures have been made with the log-rank test. Variables with a P
value of less than or equal to .1 were included in a stepwise Cox
regression analysis. Results of these multivariate analyses have
been expressed as likelihood ratios (LRs) with 95% CIs for vari-
ables with a P value of less than .05.
Results
The 30-day mortality after the first operation for all 164
patients was 3.7% (n  6). There were 21 late deaths after
the first operation. Actuarial survival was 92%  2% at 1
year, 87% 2% at 5 years, 80% 4% at 10 years, and 65%
 12% at 20 years postoperatively (Figure 2).
Multivariate analysis identified one factor that indepen-
dently increased the risk of early mortality after the first
operation. Patients in whom MAPCAs were left in the sys-
temic circulation had an increased risk of early mortality after
the first operation (LR, 12.5; 95% CI, 2.0-80.4; P  .008).
Multivariate analysis identified pulmonary artery mor-
phology as the only variable that independently increased
the actuarial risk of mortality after the first operation (P 
.01). Compared with patients with intrapericardial NPAs
(group I), patients without confluent NPAs (group III) had
an increased risk (LR, 7.8; 95% CI, 2.8-21.7; P  .001). By
comparison, patients with confluent intrapulmonary NPAs
(group II) did not have an increased risk (LR, 1.7; 95% CI,
0.6-4.9; P  .32; Figure 3).
The 30-day mortality after single-stage or multistage
correction with VSD closure was 4.4% (n  5). There were
8 late deaths after septation. The actuarial survival was 91%
 3% at 1 year, 88%  3% at 5 years, and 86%  4% at
10 years after the operation (Figure 4). Surgical strategy,
single-stage or multistage repair, had no influence on early
mortality or actuarial survival after completion (P  .98).
Among the patients who underwent complete repair with
VSD closure, the median RV/LV pressure ratio during the
perioperative period was 0.6 (range, 0.3-0.9).
Multivariate analysis identified the pulmonary artery
morphology as the only variable that independently in-
creased the risk of early mortality after complete correction
with VSD closure (P  .04). Compared with patients in
group I, patients in group III were associated with an
increased risk (LR, 75.1; 95% CI, 3.1-1802.7; P  .008).
Patients in group II were not associated with an increased
risk (LR, 7.4; 95% CI, 0.3-187.3; P  .23).
Multivariate analysis identified pulmonary artery mor-
phology as the only variable that independently increased
the actuarial risk of mortality after septation (P  .04).
Compared with patients in group I, patients in group III had
an increased risk (LR, 4.9; 95% CI, 1.2-20.5; P  .03). By
comparison, patients in group II did not have an increased
risk (LR, 3.1; 95% CI, 0.9-11.0; P  .07; Figure 5).
Five (4.4%) patients underwent early surgical or catheter
reintervention after complete correction with VSD closure.
A further 36 patients required late reintervention during the
follow-up period. The actuarial freedom from reintervention
in the septated group was 77%  2% at 1 year, 62%  5%
at 5 years, and 46%  8% at 10 years postoperatively
(Figure 6).
Figure 2. Kaplan-Meier estimated survival after the first opera-
tion (1 SEM).
Figure 3. Kaplan-Meier estimated survival after the first opera-
tion according to the NPA morphology (P  .002, log-rank test).
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Multivariate analysis identified one variable that was
associated with the risk of surgical or catheter reintervention
after complete correction with VSD closure: the caliber of
the distal pulmonary vasculature (P  .002). Compared
with patients with adequate-sized pulmonary vasculature,
patients with small pulmonary vasculature had an increased
risk (LR, 6.2; 95% CI, 2.1-18.2; P  .001). Patients with
medium-sized pulmonary vasculature were not associated
with an increased risk (LR, 2.2; 95% CI, 0.5-9.5; P  .3;
Figure 7).
Discussion
Analysis of surgical results of CHDs with MAPCAs is
difficult because of the extreme variability of the NPA and
MAPCA supply to the lungs. We have devised a classifi-
cation of the pulmonary blood supply to determine the
influence of the pulmonary artery morphology on surgical
results. Other classifications have concentrated on the intra-
pericardial pulmonary arteries as to whether they are
present, hypoplastic, or absent. We believed that a corner-
stone of a successful operation could be the presence of
confluent intrapulmonary pulmonary arteries. In fact, we
have shown this to be the case in our analysis. Thus patients
in groups I and II fair significantly better than those in group
III. We also note that attempts to reconstruct NPAs to
overcome this lack of continuity do not seem to alter the
surgical results.
The mortality for surgical intervention after the first
operation (3.7%) and after either primary or secondary
repair with VSD closure (4.4%) is satisfactory and com-
pares with the results of other reported series.12-23 However,
it is the actuarial curves that provide a better insight into the
ability to affect the natural history of this condition. Thus at
Figure 4. Kaplan-Meier estimated survival after complete correc-
tion with VSD closure (1 SEM).
Figure 5. Kaplan-Meier estimated survival after complete correc-
tion with VSD closure according to the NPA morphology (P .03,
log-rank test).
Figure 6. Kaplan-Meier estimated freedom from surgical or cath-
eter reintervention after complete correction with VSD closure
(1 SEM).
Figure 7. Kaplan-Meier estimated freedom from surgical or cath-
eter reintervention after complete correction with VSD closure
according to the overall pulmonary blood supply (P  .002,
log-rank test).
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10 years, 80%  4% of all 164 patients and 86%  4% of
the septated group are alive. The natural history of this
condition for purposes of comparison is difficult to eluci-
date. However, Bull and colleagues,24 in a group of patients
of similar age, noted a 50% mortality at 1 year of age in
patients with CHDs and MAPCAs. Thus it seems a consid-
erable improvement for these patients has been achieved.
However, the need for reintervention with cardiac cath-
eterization or surgical intervention to dilate or occlude ves-
sels and to enlarge pulmonary arteries or change valve
conduits continues to be a problem, and thus the freedom for
any reintervention in the septated group at 10 years was
only 46% 8%.25,26 Perhaps not surprisingly, patients with
small-sized pulmonary arteries had a 6-fold greater risk of
reintervention when compared with patients having ade-
quate-sized vasculature. In addition, we have only achieved
a median RV/LV pressure ratio of 0.6 after the operation.
This merely emphasizes the need to optimize the pulmonary
artery size at surgical repair.
Finally, we could discern no statistical difference in risk
between a primary repair with VSD closure or a staged
repair with VSD closure at a later date.
We have to acknowledge that this analysis is based on a
compilation of data from cardiac catheter operative records,
all of which were carefully reviewed, but naturally a sub-
jective element enters into such a classification. However, it
does allow an analysis of data that would otherwise not be
possible.
Some implications of this study are that we can be
selective in our surgical approach for patients, either apply-
ing a primary repair with VSD closure or a staged repair
with VSD closure because there is no increased risk be-
tween the 2 approaches. We should aim for more careful
intrapulmonary reconstruction of pulmonary arteries to re-
move the risk inherent and noted in this article in the group
III patients in comparison with the patients in groups I and
II. Finally, we note that it seems that the important vessels
are within the lung itself and that the intrapericardial vessels
can be reconstructed and changed as necessary without
increasing the risk to the patient but that the intrapulmonary
vessels are best treated at the time of the primary procedure.
The presence of confluent intrapulmonary vessels has a
statistically significant positive effect on successful out-
come in patients with MAPCAs.
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Discussion
Dr Gary K. Lofland (Kansas City, Mo). I do not have any
questions for you, so you are off the hook and can relax a little bit.
I do have some complimentary comments though, particularly
concerning some aspects of the article.
I suppose I was asked to discuss this article because of a certain
experience and familiarity with this disease. For reasons we are
attempting to understand, we seem to have a disproportionately
high incidence of pulmonary atresia in Kansas City, and that
incidence appears to be increasing. In 2001, we had 52 newborns
with pulmonary atresia in its various manifestations: intact septum,
VSD, VSD with MAPCAs, and patients with complex heterotaxy
with single ventricles. In 2002, it grew to 63 newborns, and in the
first 4 months of this year, we have had 35 patients, giving us about
1 to 2 new patients with pulmonary atresia per week.
With this volume of new patients, beginning in 1997, we
adopted what we believe is a very aggressive approach that is very
similar to that outlined by the authors of this article, except that we
have attempted to accelerate the process just a bit.
All babies presenting with this diagnosis in our institution
undergo cardiac catheterization as a newborn. This enables docu-
mentation of nonductile dependency, definition of the NPAs if
present, and description of the collateral arteries.
We then bring these babies back at 3 months of age and
recatheterize them, looking for changes in the NPAs and the
collateral arteries. It is amazing how much growth of any NPAs
that happen to be present can occur in the first 3 months.
Failure to see growth during that time is disappointing. A 1-mm
pulmonary artery at birth is still a 1-mm NPA at 3 months, and this
means it is going to be a long day in the operating room.
We initiate surgical intervention immediately after this cathe-
terization, and that intervention is delayed only by intercurrent
viral illness. We try not to do these during respiratory syncytial
virus season.
I noticed in your article that you used deep hypothermia and
circulatory arrest. Although we would naturally hold that perfusion
technique in reserve, we have chosen instead to use a vacuum-
assisted normothermic bypass and have been very satisfied with
the degree of cardiopulmonary decompression we get with that
technique. Therefore I would propose that as an alternative. That
perfusion technique has been described by my chief perfusionist in
perfusion journals.
Now in your article, you have mentioned the association of
22Q11 deletion patterns and conal truncal defects. This association
was also mentioned in the congenital course yesterday, but mi-
crodeletions of the 22nd chromosome are seen in only about 25%
to 30% of these patients, and therefore our knowledge of this is
still very, very rudimentary, although it is fascinating.
Driven in part by the numbers of patients we see with this
disease and active and willing sections of molecular genetics and
clinical pharmacology, about 4 months ago, we acquired and
developed the technology to perform a microarray analysis for a
little over 17,000 different genes by using very small tissue sam-
ples. I would like to share some of that preliminary data with you
because it is mentioned in your article.
In patients with pulmonary atresia, we have found genetic
expression occurring in the pulmonary arteries that seems to be
very different than the genetic expression occurring in myocar-
dium, pericardium, and thymus in the same patients and in normal
patients with no cardiac disease.
One thinks of genetic expression as being uniform in all the
tissues in an individual, but that is proving to not be the case. This
variability of expression seems to be single-nucleotide polymor-
phisms (SNPS).
If these preliminary findings prove to be true, their significance
lies in the fact that SNPS can be manipulated. Indeed, the manip-
ulation of single-nucleotide polymorphisms is the foundation of
the knockout mouse models that are used in pharmacokinetic and
other studies. We now know that the genes in these animal models
can be turned on, and they can be turned off.
It is intriguing to think that in the future, the management of
these patients might include the ability to turn genes on or off that
are responsible for the growth and development, or lack thereof, of
pulmonary arteries, thereby possibly giving us something a bit
better with which to work.
This is an excellent article, and the authors should be congrat-
ulated for quantitatively demonstrating something that those of us
who care for numbers of these patients have qualitatively under-
stood or at least suspected.
Outcomes in these patients are not affected at all by the inabil-
ity to close the VSD at the time of unifocalization and right
ventricular PA connection and is very much dependent on the
presence and size of the NPAs.
Dr R. Ungerleider. Gary, before you leave the microphone,
just in case anybody wants to look up the reference, is it Gary Grist
who is your chief perfusionist?
Dr Lofland. Yes.
Dr Griselli. I would like to make a comment regarding some
data on the article and on the presentation.
First of all, our classification in terms of single-stage and
multistage repair is a bit different from other proposals in the
literature. In our article and in our presentation, single-stage repair
means one operation only. It means that in the same operation we
unifocalize and close the VSD. Of course, there is this matter of
nomenclature difference.
Basically, single-stage unifocalization happens in different pa-
tients, but this has been included in a multistage repair because
there is more than one anesthetic and more than one operation.
Included is multistage repair, which involves those patients who
had palliative surgery without unifocalization and subsequently
had a complete single-stage unifocalization with or without closure
of the VSD. Therefore the number is a bit different than the one
shown by our classification, and we tried to do it in a different way.
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Regarding the Di George syndrome, we had 222 patients iden-
tified by means of the FISH test; in our institution the FISH test
was started routinely for conal truncal abnormalities around Jan-
uary 1995. Therefore probably we missed something, but I think
this is a common problem for other workers I have seen in
literature.
Dr Thomas L. Spray (Philadelphia, Pa). I just had a ques-
tion, and it might be in your article, but in your new classifi-
cation, when you are talking about confluent, I assume, intra-
parenchymal pulmonary arteries, you mentioned that it is
unilateral or bilateral.
Was there any difference in terms of outcome, whether it
was unilateral or bilateral, and did that determine whether you
tried to do a single-stage unifocalization or a staged unifocal-
ization?
Dr Griselli. No, there was no difference between unilateral or
bilateral confluent intrapulmonary PAs.
There were differences between unilateral and bilateral com-
pared with the MAPCAs, definitely in outcome. The patient had
only MAPCAs. That was the only difference noted, not between
unilateral or bilateral, no.
Dr Adriano Carotti (Rome, Italy). Did you find any difference
between the single-stage approach and the multistage approach
either in terms of hemodynamic results, namely, the RV/LV pres-
sure ratio after VSD closure, or of major perioperative morbidity,
such as a paralysis of the phrenic nerve.
Furthermore, concerning 22Q11 microdeletion, which occurred
in our experiences as much as 40% of cases and related signifi-
cantly with postsurgical prognosis, I would like to know whether,
in your series, chromosome 22Q11 microdeletion affected periop-
erative mortality, morbidity, or both at all.
Dr Griselli. There was no difference in terms of complication
for different groups. We had 21 major complications, complica-
tions that required intervention, and there were no differences
within the 3 groups.
Regarding the microdeletion, again, there were no differences
among the 3 groups, although we reviewed the data from another
point of view, because this is just an aspect of the MAPCA
surgery. Our idea is that we want to explain why some patients
who basically had a better anatomy, such as intrapulmonary pul-
monary arteries, require more reoperation, but we are looking at
this for a further study.
Dr Antonio F. Corno (Lausanne, Switzerland). What are the
consequences of your study? On the basis of the observation you
reported, did you change any policy in your approach to these
patients? Are you considering any change, particularly in the group
of patients with MAPCAs only?
Dr Griselli. There is no change in terms of the operation, but
what before was important for us, like finding the intrapericardial
pulmonary arteries in terms of results, now we focus more on
finding confluence at the intrapulmonary level, which seems to be
a more important thing for a surgeon to find the confluence
between the chest and the hilum. Then you can join them up
centrally, as you like.
But more important is not just what you can find inside the
pericardium but what you can find in the hilum of the lungs. If you
find a good confluence, it is a good prognostic factor, even if you
do not have intrapericardial PAs.
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